dc.contributor.author | Mok, T. | |
dc.contributor.author | Bondarenko, I. | |
dc.contributor.author | Kubota, K. | |
dc.contributor.author | Lubiniecki, G. | |
dc.contributor.author | Zhang, J. | |
dc.contributor.author | Kush, D. | |
dc.contributor.author | Turna, H. | |
dc.contributor.author | Lopes, G. | |
dc.contributor.author | Wu, Y. | |
dc.contributor.author | Kudaba, I. | |
dc.contributor.author | Kowalski, D. | |
dc.contributor.author | Cho, B. | |
dc.contributor.author | De Castro, G. | |
dc.contributor.author | Srimuninnimit, V. | |
dc.contributor.author | Laktionov, K. | |
dc.date.accessioned | 2021-03-06T20:18:41Z | |
dc.date.available | 2021-03-06T20:18:41Z | |
dc.date.issued | 2018 | |
dc.identifier.citation | Lopes G., Wu Y., Kudaba I., Kowalski D., Cho B., Turna H., De Castro G., Srimuninnimit V., Laktionov K., Bondarenko I., et al., "Phase 3 KEYNOTE-042 Study: Pembrolizumab vs Platinum-Based Chemotherapy as 1l Therapy for Advanced NSCLC with a PD-L1 TPS >= 1%", JOURNAL OF THORACIC ONCOLOGY, cilt.13, 2018 | |
dc.identifier.issn | 1556-0864 | |
dc.identifier.other | av_f9a622c9-2dea-48b2-8ac3-007b674a2fc6 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/163506 | |
dc.identifier.uri | https://doi.org/10.1016/j.jtho.2018.07.020 | |
dc.language.iso | eng | |
dc.subject | Göğüs Hastalıkları ve Allerji | |
dc.subject | İç Hastalıkları | |
dc.subject | Onkoloji | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | SOLUNUM SİSTEMİ | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | ONKOLOJİ | |
dc.subject | Klinik Tıp | |
dc.title | Phase 3 KEYNOTE-042 Study: Pembrolizumab vs Platinum-Based Chemotherapy as 1l Therapy for Advanced NSCLC with a PD-L1 TPS >= 1% | |
dc.type | Makale | |
dc.relation.journal | JOURNAL OF THORACIC ONCOLOGY | |
dc.contributor.department | İstanbul Üniversitesi , , | |
dc.identifier.volume | 13 | |
dc.identifier.issue | 9 | |
dc.contributor.firstauthorID | 256454 | |